Menu
Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 5
New advances in the treatment of Clostridium difficile infection (CDI)
Authors Hedge DD, Strain JD, Heins JR, Farver DK
Published 10 October 2008 Volume 2008:4(5) Pages 949—964
DOI https://doi.org/10.2147/TCRM.S3145
Review by Single anonymous peer review
Peer reviewer comments 3
Dennis D Hedge, Joe D Strain, Jodi R Heins, Debra K Farver
South Dakota State University College of Pharmacy, Brookings, SD 57007, USA
Abstract: Clostridium difficile infections (CDI) have increased in frequency throughout the world. In addition to an increase in frequency, recent CDI epidemics have been linked to a hypervirulent C. difficile strain resulting in greater severity of disease. Although most mild to moderate cases of CDI continue to respond to metronidazole or vancomycin, refractory and recurrent cases of CDI may require alternative therapies. This review provides a brief overview of CDI and summarizes studies involving alternative antibiotics, toxin binders, probiotics, and immunological therapies that can be considered for treatment of acute and recurrent CDI in severe and refractory situations.
Keywords: Clostridium difficile, antibiotics, probiotics, immunological therapy
© 2008 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.